Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,724,588
  • Shares Outstanding, K 84,883
  • Annual Sales, $ 371,210 K
  • Annual Income, $ -153,610 K
  • 60-Month Beta 1.76
  • Price/Sales 12.59
  • Price/Cash Flow N/A
  • Price/Book 2.37
Trade CRSP with:

Options Overview Details

View History
  • Implied Volatility 70.70% ( -0.45%)
  • Historical Volatility 35.48%
  • IV Percentile 77%
  • IV Rank 56.54%
  • IV High 96.14% on 10/06/23
  • IV Low 37.60% on 09/14/23
  • Put/Call Vol Ratio 0.41
  • Today's Volume 4,343
  • Volume Avg (30-Day) 7,710
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 90,263
  • Open Int (30-Day) 107,469

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.63
  • Number of Estimates 11
  • High Estimate -1.19
  • Low Estimate -2.07
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -143.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.28 +4.10%
on 04/19/24
73.09 -22.70%
on 03/26/24
-15.11 (-21.10%)
since 03/22/24
3-Month
54.28 +4.10%
on 04/19/24
91.10 -37.98%
on 02/22/24
-9.69 (-14.64%)
since 01/23/24
52-Week
37.55 +50.47%
on 10/23/23
91.10 -37.98%
on 02/22/24
+4.49 (+8.63%)
since 04/21/23

Most Recent Stories

More News
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?

Vertex is broadening its portfolio.

CRSP : 56.43 (+1.38%)
VRTX : 404.91 (+1.25%)
ALPN : 64.55 (-0.05%)
3 Cathie Wood Stocks Analysts Like Better Than Tesla

While Ark Invest scoops up Tesla, these three Cathie Wood picks have higher analyst ratings than the struggling EV leader.

TSLA : 154.67 (+8.88%)
ARKK : 44.00 (+3.29%)
CRSP : 56.43 (+1.38%)
RBLX : 36.44 (+4.23%)
PATH : 19.54 (+3.44%)
VRTX : 404.91 (+1.25%)
EA : 127.14 (+0.02%)
TTWO : 141.74 (+1.27%)
META : 497.48 (+3.27%)
3 Magnificent Stocks That Could Double or More by 2030

There's no guarantee these stocks will double by 2030, but their growth prospects look great.

CRSP : 56.43 (+1.38%)
LLY : 745.69 (+1.96%)
VKTX : 64.63 (+1.22%)
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics

These rising drugmakers have serious arguments in their favor.

CRSP : 56.43 (+1.38%)
VKTX : 64.63 (+1.22%)
VRTX : 404.91 (+1.25%)
Bull Market and Beyond: 3 Stocks Just Waiting to Soar

These stocks, a bargain today, are players to hold on to for the long term.

CRSP : 56.43 (+1.38%)
LLY : 745.69 (+1.96%)
PFE : 26.30 (+0.15%)
MRNA : 108.01 (+3.40%)
NTLA : 21.53 (-1.37%)
DNA : 0.8705 (+3.29%)
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics

These companies are in the early days of their growth stories.

IOVA : 11.85 (+4.68%)
CRSP : 56.43 (+1.38%)
3 Unstoppable Stocks to Buy Hand Over Fist in April

These stocks have exceptionally bright prospects.

CRSP : 56.43 (+1.38%)
LLY : 745.69 (+1.96%)
VRTX : 404.91 (+1.25%)
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000

Each of these three companies are entering a new era of growth.

PFE : 26.30 (+0.15%)
CRSP : 56.43 (+1.38%)
MDT : 81.29 (+0.89%)
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

The price could be right for these three biopharma stocks.

AXSM : 73.08 (+2.78%)
CRSP : 56.43 (+1.38%)
PFE : 26.30 (+0.15%)
Is It Too Late to Buy CRISPR Therapeutics Stock?

The biotech has been making a lot of noise since late last year.

CRSP : 56.43 (+1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 59.50
2nd Resistance Point 58.21
1st Resistance Point 56.94
Last Price 56.43
1st Support Level 54.38
2nd Support Level 53.09
3rd Support Level 51.82

See More

52-Week High 91.10
Fibonacci 61.8% 70.64
Fibonacci 50% 64.32
Fibonacci 38.2% 58.01
Last Price 56.43
52-Week Low 37.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar